Article Combinatorial treatment using bevacizumab/pemetrexed loaded core-shell silica nanoparticles for non-small cell lung cancer

Deepika Radhakrishnan ORCID (Global Innovative Center for Advanced Nanomaterials, The University of Newcastle) ; Vaishwik Patel ORCID (Global Innovative Center for Advanced Nanomaterials, The University of Newcastle) ; Shan Mohanan (Global Innovative Center for Advanced Nanomaterials, The University of Newcastle) ; Sharon Wong (Global Innovative Center for Advanced Nanomaterials, The University of Newcastle) ; Jacob Netherton (School of Biomedical Sciences and Pharmacy, The University of Newcastle) ; Ajay Karakoti (Global Innovative Center for Advanced Nanomaterials, The University of Newcastle) ; Ajayan Vinu (Global Innovative Center for Advanced Nanomaterials, The University of Newcastle)

Combinatorial treatment using bevacizumab pemetrexed loaded core-shell silica nanoparticles for non-small cell lung cancer.pdf
Download file (5.09 MB)
Download as zip (4.45 MB)
Collection

Citation
Deepika Radhakrishnan, Vaishwik Patel, Shan Mohanan, Sharon Wong, Jacob Netherton, Ajay Karakoti, Ajayan Vinu. Combinatorial treatment using bevacizumab/pemetrexed loaded core-shell silica nanoparticles for non-small cell lung cancer. Science and Technology of Advanced Materials. 2023, 24 (), 2274819. https://doi.org/10.48505/nims.4315

Description:

(abstract)

Non-small cell lung cancer (NSCLC) is a life-threatening cancer associated with a higher mortality rate. Despite promising results shown by combination therapies, there remains a need for efficient drug delivery materials capable of combining various drugs, imaging agents, and targeting agents to enhance treatment efficacy. In this study, we present the synthesis of novel core-shell hollow mesoporous silica nanoparticles (@MSN) with bimodal porosity and a large surface area (694 m2/g) to facilitate targeted drug delivery for NSCLC treatment. The hollow core-shell structure enables the loading of a substantial quantity of the pemetrexed drug, up to 839 µg/mg, with a sustained release of 20% within 48 hours. The MSN is surface functionalised with amino and carboxyl groups to accommodate an imaging agent and facilitate the attachment of the targeting drug bevacizumab. These particles exhibit rapid uptake by both A549 and PC-9 cells. Moreover, the targeting by bevacizumab leads to higher cytotoxicity within 48 hours and induces apoptosis more effectively than the non-functionalised samples. As a versatile drug delivery platform, the hollow core-shell MSN demonstrated in this study holds great potential for various drug delivery applications.

Rights:

Keyword: Non-small cell lung cancer (NSCLC), combinatorial treatment, core-shell silica nanoparticles

Date published: 2023-12-31

Publisher: Taylor & Francis

Journal:

  • Science and Technology of Advanced Materials (ISSN: 14686996) vol. 24 2274819

Funding:

Manuscript type: Author's version (Accepted manuscript)

MDR DOI: https://doi.org/10.48505/nims.4315

First published URL: https://doi.org/10.1080/14686996.2023.2274819

Related item:

Other identifier(s):

Contact agent: Ajayan Vinu (Global Innovative Center for Advanced Nanomaterials, The University of Newcastle) Ajayan.Vinu@newcastle.edu.au

Updated at: 2023-11-08 13:52:01 +0900

Published on MDR: 2023-11-09 13:30:15 +0900

Filename Size
Filename Combinatorial treatment using bevacizumab pemetrexed loaded core-shell silica nanoparticles for non-small cell lung cancer.pdf (Thumbnail)
application/pdf 		Size 5.09 MB Detail